[511] INTRANASAL SCOPOLAMINE SPRAY PROVIDES MOTION SICKNESS PROTECTION WHILE DEMONSTRATING RAPID ABSORPTION RATES AND NO IMPACT ON COGNITIVE PERFORMANCE

摘要

BACKGROUND: Motion sickness (MS) is a problem for military operations. Scopolamine is one of the most effective anti-MS medications; however, the most common administration routes (transdermal and oral) have significant drawbacks, including delayed onset of action and dose-related side effects. Low dose, intranasal scopolamine (INSCOP) administration is an alternative which promises rapid absorption and fewer side effects. Here, we report the complete Pharmacokinetic (PK) and Efficacy results. METHODS: In the PK phase (n=19), subjects received 0.2 mg INSCOP followed by eight hours of monitoring. In the Efficacy phase (n=23), subjects underwent two counterbalanced sessions of mechanical rotation 40-50 minutes after receiving 0.2 mg INSCOP or placebo in double-blinded fashion. During rotation, subjects performed paced head tilts, with rotation speed accelerating each minute to a maximum of 40 rpm. Self-reported symptomology data were collected prior to, during, and following rotation. Blood samples, vitals, cognitive performance and subjective fatigue levels were collected.